Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, Professor of Medicine at the University of Central Florida, and at Loma Linda University Health, shared a post on LinkedIn:
“SITC25 presentation: Insights from a translational study of patients from a Phase I clinical trial evaluating a novel immunotherapy-
Diacylglycerol kinases alpha (DGKα) and zeta (DGKζ) are intracellular checkpoints expressed in T-cells that attenuate T cell activation by modulating T cell receptor (TCR) signaling and limiting recognition of tumor antigens. The mechanism is phosphorylation of the secondary messenger diacylglycerol (DAG) to form phosphatidic acid. The ex vivo addition of DGKζ inhibitor to peripheral blood mononuclear cells of patients receiving DGKα inhibitor monotherapy demonstrated synergistic elevation in IFNγ and IL2.
Thus, the combination of DGKζ + DGKα inhibitor therapy warrants investigation. Pleased to collaborate from Adventhealth Cancer Institute, AdventHealth Central Florida, Orlando, Florida with Bayer with our great team.”
More posts featuring Guru Sonpavde.